• français
    • English
  • English 
    • français
    • English
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.
BIRD Home

Browse

This CollectionBy Issue DateAuthorsTitlesSubjectsJournals BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesSubjectsJournals

My Account

Login

Statistics

View Usage Statistics

Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting

Thumbnail
Date
2021
Dewey
Economie sociale
Sujet
Atrial fibrillation; Cost; Percutaneous coronary intervention; Bleeding complications; Thrombosis
JEL code
I.I1.I18; I.I1.I12
Journal issue
journal of Cardiology
Volume
77
Number
1
Publication date
2021
Article pages
93-99
Publisher
Elsevier
DOI
http://dx.doi.org/10.1016/j.jjcc.2020.07.018
URI
https://basepub.dauphine.fr/handle/123456789/21543
Collections
  • LEDa : Publications
Metadata
Show full item record
Author
Mehran, Roxana
116451 Mount Sinai Medical Center
234690 Cardiovascular Research Foundation
Vogel, Birgit
116451 Mount Sinai Medical Center
Lévy, Pierre
163517 Laboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
559342 Laboratoire d'Economie de Dauphine [LEDa]
Type
Article accepté pour publication ou publié
Abstract (EN)
Patients undergoing percutaneous coronary intervention (PCI) have an increased risk of both ischemic events and bleeding complications resulting from antithrombotic therapy. These events are particularly common in patients with a concomitant indication for oral anticoagulation, such as those with atrial fibrillation, and are associated with a substantial healthcare resource burden. Advances in procedural aspects of PCI have led to marked improvements in outcomes and a consequent reduction in the costs resulting from PCI-associated complications. Furthermore, recent randomized clinical trials have investigated the optimal antithrombotic strategy in the specific case of patients with atrial fibrillation undergoing PCI, leading to a shift toward the tailoring of antithrombotic therapy according to the patient’s individual stroke and bleeding risks. Here we review these recent advances, with a particular focus on the improvements in antithrombotic strategies offered by the non-vitamin K antagonist oral anticoagulants

  • Accueil Bibliothèque
  • Site de l'Université Paris-Dauphine
  • Contact
SCD Paris Dauphine - Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16

 Content on this site is licensed under a Creative Commons 2.0 France (CC BY-NC-ND 2.0) license.